Drug-drug interaction-related uncontrolled glycemia

Context: The literature of drug-drug interaction (DDI)-related uncontrolled causality, and preventability of DDI-induced UCG (HbA1c >7%) in outpatients glycemia (UCG) among outpatients with Type 2 diabetes mellitus is still limited. Aims: The aim of this study is to identify the prevalence, mechanism, severity, with Type 2 diabetes. Settings and Design: A cross-sectional study was conducted in Penang General Hospital. Methods: A computerized system for DDI checking was used to assess the severity and mechanism of DDIs. Drug interaction probability scale was used to evaluate the likelihood of DDIs. Preventability of DDIs has been determined by the instrument of Hallas. The UCG prevalence related to DDIs was further assessed. Statistical Analysis Used: SPSS 21.00 was used in this study. Results: From 425 outpatients with HbA1c% test, their mean age was 58.7 ± 12.8 years. Only 225 (52.9%) cases had controlled glycemia while 200 (47.1%) cases with UCG. They had multiple comorbidities, with a mean number of 3.8 ± 2.2/patient and often prescribed with multiple medications, with a mean number of 6.33 ± 4.67/patient. It has been detected that 86 DDIs causing UCG in 46 patients (23%) with range of (1-4) DDIs per patient. Drugs with DDI-induced UCG were as follows: diuretics (79%), salbutamol (9.2%), cortisones (5.8%), and others (6%). The majority of these DDIs were categorized as possible (77.9%) and preventable (37%). Conclusion: Nearly one-quarter of UCG was induced by DDIs; most of these DDIs are possible, and more than one-third are preventable. It was concluded that thiazide diuretics have the highest prevalence of DDI-related UCG

ETR 300 : Creative Ceiling Enterprise / Samidah Jindang... [et al.]

Creative Ceiling Enterprise adalah sebuah perniagaan yang menghasilkan produk siling berukir.Creative Ceiling juga merupakan satu-satunya syarikat bumiputra yang menceburi perniagaan ini. Syarikat ini mengeluarkan beberapa jenis siling. Antara siling yang dikeluarkan ialah : (a) Centra Panel Creative (b) Cornices Creative (c) Ceiling board Creative. Centra panel Creative dan Cornices Creative merupakan jenis siling yang digunakan di bangunan mewah seperti hotel, kondiminium, rumah banglo, istana dan sebagainya. Ceiling board Creative banyak digunakan seperti rumah, pejabat, institusi pengajian tinggi dan sebagainya. Lokasi perniagaan ini beralamat di Kampung Titi Besi, 02600 Arau, Perlis

Business model shifts: masjid kitchens as soup kitchens, jobs employment and empowering asnaf entrepreneurs, and income generation for the masjid

The UNICEF report titled “Families on The Edge” dated October 2020, stated that COVID-19 crisis has pushed more low-income or poor B40 urban Malaysian families into poverty. The poverty rate of these B40 urban families in 2020 is higher than last year, with 50% of the families now living in absolute poverty. 70% of these households reported that COVID-19 had affected their ability to meet their basic living expenses. 37% reporting that they struggle to purchase enough food for their families, while 35% are unable to pay their bills on time. This paper adapted the Design Thinking (DT) methodology. This is to understand and define the key B40 urban families problems; ideation of possible solution options, validation of solution options by various customer segments; and to suggest a conceptual business model as possible solution. This includes conducting literature review and benchmarking, and conducting interviews. An initial business model using Business Model Canvas (BMC) framework was formulated; tested and validated by various customer segments. Hence, the main contribution of this paper is to offer a validated conceptual business model in transforming current masjid kitchen (or mKitchen) as a potential in (a) providing soup kitchen for the poor B40 and Asnaf community, (b) providing job employment while reskilling, empowering, and nurturing the Asnaf as food entrepreneurs, and (c) generating income for the masjid via rental of existing kitchen facilities. This is to turn the Asnaf community ‘Dari Penerima Zakat ke Pembayar Zakat’ or from Zakat receivers to Zakat contributors. The conceptual mKitchen business model can be adopted or adapted for possible implementation, in general, by masjid or mosques

Inaugural edu-action journey with cooperative behavior (Ta’awun) of mKitchen® students in free food for the needy

This book narrates the inaugural edu-action journey with cooperative behaviour (ta’awun) in free food for the needy people at IIUM mKitchen® with Sri Mutiara Teguh Enterprise (cafeteria vendor at Mahallah Aminah IIUM Gombak). The main objective of the project is to transform Mahallah kitchen as a platform to provide free food, to up skill in food-preneurship, to create new employment opportunities, to give empowerment and to nurture entrepreneurship (3Es) among students. Ta’awun refers to cooperative behaviour among the participants, the sponsors, and the beneficiaries in initiating, planning, sponsoring, executing and evaluating the mKitchen® project at Sri Mutiara Teguh Enterprise, Mahallah Aminah. The journey officially started on 1 July 2021 with various student development entities at IIUM. After providing a 4-day online training on business model and plan, financial modelling, and digital marketing, the steering committee has decided to provide the real experience to the students. In conjunction with Malaysia Day on 16 September 2021, the students proposed for cooking and distributing free food to the needy as part of the first proof-of-concept for mKitchen students with the “Keluarga Malaysia” spirit. Nevertheless, the project has to adhere to movement restriction by the authority to prevent the spread of coronavirus disease (COVID-19). The second proof-of-concept is cooking food based on mKitchen students’ business plan

A Journey of Ta’awun (Cooperative Behaviour) in Edu-Action at IIUM Mkitchen® and Masjid al-Syakirin Gombak (MASG)

This book narrates the journey of ta’awun (cooperative behaviour) at IIUM Mkitchen® project with Masjid Al-Syakirin Gombak (MASG). The main objective of the project is transform the mosque as a platform to provide free food, to up skill in foodpreneurship, to create new employment opportunities, to give empowerment and to nurture entrepreneurship (3Es) for poor and needy people in the surrounding area of it. Ta’awun refers to cooperative behaviour among the participants, the sponsors, and the beneficiaries in initiating, planning, sponsoring, executing and evaluating the Mkitchen® project at Masjid Al-Syakirin Gombak (MASG). The journey officially started on 24th January 2021 through its first meeting among the interested as well as committed members. After executing two events, the project was continued with a full scale project for a month. The project has secured its proof of concept (POC). Nevertheless, the project has been continued with a small scale due to the movement restriction by the authority to prevent the spread of coronavirus disease (COVID-19)

Redesign business model of masjid kitchens as soup kitchens, providing jobs employment and nurturing of asnaf as entrepreneurs, and income generation for the masjid

A survey conducted by the Department of Statistics Malaysia in May 2020 has found that: (a) 46.6% of self-employed respondents had reported losing their jobs; (b) an estimated 90% respondents were still working with lower than usual salaries; (c) more than two-thirds (71.4%) of self-employed respondents have sufficient financial savings for less than one month; and (d) the majority of respondents said they are unprepared if the duration of the MCO was extended except for employees under Government Linked Companies and multinational companies. In the “Families on The Edge” UNICEF report dated October 2020, COVID-19 crisis has pushed more low-income (or B40) urban Malaysian families into poverty. The poverty rate in the B40 community is higher than last year, with 50% of the families now living in absolute poverty. 70% of these households reported that COVID-19 had affected their ability to meet their basic living expenses, with 37% reporting that they struggle to purchase enough food for their families while 35% are unable to pay their bills on time. Hence, the main objectives of this paper is to offer a conceptual business model in turning masjid kitchens (or mKitchen) as a potential (a) soup kitchen for the B40 and Asnaf community, (b) job employment and nurturing of the Asnaf as entrepreneurs, and (c) income generation for the masjid via rental of kitchens. This is to turn the Asnaf community ‘Dari Penerima Zakat ke Pembayar Zakat’. The conceptual mKitchen business model can be adapted for possible implementation by masjid or mosques

Budiman Mahallah kitchen

This book narrates budiman journey in Mahallah Kitchen. Budiman Mahallah Kitchen who are searching for adab (virtue), budi (kindness) and sejahtera (peace). By doing so, budiman and budiwati will have the capacity of bijak berbudi (wisdom in kindness), berani (brave) and bijaksana (full with wisdom). Budiman and budiwati with these attributes will manifest budi bahasa (rasa), budi pekerti (rupa), and budi bicara (roh). Thus, budiman and budiwati will have sejahtera niat (peaceful intentions), sejahtera keputusan (peaceful decisions), and sejahtera tindakan (peaceful actions). Budiman and budiwati will be continuously making contribution of sejahtera to self and others. The foundation of adab (virtue) is based on formula A-D-A-B. A is amanah (trustworthy), dakar (staunch), akhlak (ethics), and bestari (intelligent)

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049